Gravity Analytica

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

NKTR 10.31.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-07

Name of Upcoming Event:Nektar Conference Call

Full Press Release SEC Filings Our NKTR Tweets

About Gravity Analytica

Recent Filings

SAN FRANCISCO,Oct. 31, 2024/PRNewswire/ --Nektar Therapeutics(Nasdaq: NKTR) will announce its financial results for the third quarter 2024 onThursday, November 7, 2024, after the close ofU.S.-based financial markets.Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website:http://ir.nektar.com/. The web broadcast of the conference call will be available for replay throughDecember 7, 2024.

To access the conference call, please pre-register atNektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.

AboutNektar TherapeuticsNektarTherapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction inautoimmuneand chronic inflammatory diseases.Nektar'slead product candidate,rezpegaldesleukin(REZPEG, or NKTR-358), is a novel, first-in-class regulatoryTcell stimulator being evaluated in two Phase 2b clinical trials, one inatopicdermatitis and one inalopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type IIagonistantibody.Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptoragonistdesigned to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.Nektaris headquartered inSan Francisco, California. For further information, visitwww.nektar.comand follow us on LinkedIn.

Contacts:

For Investors:VivianWuofNektarTherapeutics(628) 895-0661

For Media:Madelin HawtinLifeSciCommunications603-714-2638mhawtin@lifescicomms.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-third-quarter-2024-on-thursday-november-7-2024-after-close-of-us-based-financial-markets-302293320.html

SOURCENektar Therapeutics

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com